← Search & browse all drugs
RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Respiratory stimulants
prethcamide
R07AB06
Forms & Strengths
- Tablets 15 mg
- Syrup 5 mg/5 mL
- Oral solution 10 mg/mL
Adult Dosing
- 30 mg PO q6‑8 h for acute non‑productive cough (max 120 mg/day)
- 15 mg PO q6 h for severe cough refractory to lower dose
Pediatric Dosing
- Not recommended <6 years (contraindicated)
- 6‑12 years: 7.5 mg PO q6‑8 h (max 30 mg/day)
Indications
- Symptomatic relief of non‑productive cough associated with upper respiratory tract infection
- Cough suppression in chronic bronchitis when other causes excluded
Mechanism of Action
- Centrally acting antitussive; suppresses medullary cough centre via sigma‑1 receptor agonism and NMDA‑receptor antagonism
Contraindications
- Hypersensitivity to prethcamide or excipients
- Severe hepatic impairment
- Concurrent MAO‑inhibitor therapy
- Children <6 years
Adverse Reactions
- Drowsiness
- Dizziness
- Nausea and vomiting
- Constipation
- Rare hallucinations or visual disturbances
- Respiratory depression at supratherapeutic doses
Drug Interactions
- Enhanced CNS depression with alcohol, benzodiazepines, opioid analgesics
- Risk of serotonin syndrome with MAO inhibitors or serotonergic agents
- Increased prethcamide levels with strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine)
- Additive anticholinergic effects with antihistamines, tricyclic antidepressants
Curated Content: Needs Vetting Before Put to Clinical Use